Skip to main content

Table 1 Effects of fulvestrant, HRGβ1 or a combination of the two treatments on immunocytochemically determined nuclear Ki-67 positivity in MCF-7, T47D, BT474 and MDAMB361 cells

From: Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1

 

Nuclear Ki-67 positivity, %

Cell type

Control

Fulvestrant

HRGβ1

Fulvestrant + HRGβ1

MCF-7

97 ± 1.2

55 ± 4.5*

90 ± 0.4

89 ± 1.8†

T47D

80 ± 2.2

41 ± 3.6*

63 ± 2.7**

49 ± 5.8

BT474

38 ± 2.2

13 ± 1.3*

48 ± 2.2***

50 ± 1.3††

MDAMB361

82 ± 0.9

38 ± 1.8*

59 ± 2.2**

71 ± 2.2††

  1. HRGβ1, heregulin β1. Nuclear positivity percentage values are expressed as means ± standard deviation of the assessment of six fields of view per coverslip in triplicate experiments.
  2. *P < 0.001 versus control, **P < 0.05 versus control, ***P < 0.01 versus control, P < 0.01 versus fulvestrant, ††P < 0.001 versus fulvestrant.